Table 2.

Sofosbuvir (SOF)/velpatasvir (VEL)/voxilaprevir (VOX) efficacy real-life data

	Study–first author
	Kaiser Permanente– Saxena et al. [14]	TRIO Network– Bacon et al. [15]	Veteran Administration–Belperio et al. [16]
Treatment regimen	SOF/VEL/VOX±RBV 12 w	SOF/VEL/VOX±RBV 12 w	SOF/VEL/VOX 12 w
DAA experience in the overall cohort	85%	88%	100%
SVR 12 among experienced only	97% (208/214)	99% (163/165)	91% (501/551)

RBV, ribavirin; w, weeks; DAA, direct acting antiviral; SVR12, sustained virological response at week 12.